Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Zai Lab LTD Transaction History

Meag Munich Ergo, Kapitalanlagegesellschaft Mb H

$2.7 Billion
Q1 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 13, 2022	SELL	$27.77 - $64.4 $261,038 - $605,360	-9,400 Closed	0 $0
Q2 2021 Jul 16, 2021	BUY	$125.11 - $180.0 $650,572 - $936,000	5,200 Added 123.81%	9,400 $1.66 Million
Q1 2021 Apr 20, 2021	BUY	$126.27 - $191.71 $530,334 - $805,182	4,200 New	4,200 $560,000

Others Institutions Holding ZLAB

# of Institutions

124

Shares Held

39.9M

Call Options Held

41.2K

Put Options Held

190K

Wellington Management Group LLP Boston, MA

6.66M
Shares

$115 Million
0.02% of portfolio
Capital World Investors Los Angeles, CA

5.68M
Shares

$97.9 Million
0.02% of portfolio
Janus Henderson Group PLC London, X0

4.43M
Shares

$76.3 Million
0.04% of portfolio
Woodline Partners LP San Francisco, CA

2.6M
Shares

$44.7 Million
0.4% of portfolio
Viking Global Investors LP

2.05M
Shares

$35.3 Million
0.12% of portfolio

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $1.69B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H, based on Form 13F filings with the SEC.

News

Stay updated on Meag Munich Ergo, Kapitalanlagegesellschaft Mb H with notifications on news.

Account